ATHE Alterity Therapeutics Limited Stock Quote

ATHE [NASD]

Index	-	P/E	-	EPS (ttm)	-0.43	Insider Own	18.70%	Shs Outstand	34.51M	Perf Week	-3.68%
Market Cap	54.48M	Forward P/E	-	EPS next Y	-0.01	Insider Trans	0.00%	Shs Float	20.81M	Perf Month	0.77%
Income	-11.30M	PEG	-	EPS next Q	-	Inst Own	2.60%	Short Float	4.05%	Perf Quarter	-6.43%
Sales	0.03M	P/S	1935.24	EPS this Y	40.00%	Inst Trans	-4.25%	Short Ratio	0.13	Perf Half Y	-16.03%
Book/sh	0.65	P/B	2.02	EPS next Y	-	ROA	-64.20%	Target Price	-	Perf Year	-37.02%
Cash/sh	-	P/C	-	EPS next 5Y	-	ROE	-73.60%	52W Range	1.09 - 3.58	Perf YTD	-2.24%
Dividend	-	P/FCF	-	EPS past 5Y	9.00%	ROI	-	52W High	-63.41%	Beta	1.65
Dividend %	-	Quick Ratio	10.90	Sales past 5Y	-	Gross Margin	-	52W Low	20.18%	ATR	0.05
Employees	11	Current Ratio	10.90	Sales Q/Q	1.50%	Oper. Margin	-	RSI (14)	45.91	Volatility	3.77% 3.69%
Optionable	No	Debt/Eq	0.00	EPS Q/Q	67.80%	Profit Margin	-	Rel Volume	0.04	Prev Close	1.29
Shortable	Yes	LT Debt/Eq	0.00	Earnings	-	Payout	-	Avg Volume	6.71M	Price	1.31
Recom	-	SMA20	-2.20%	SMA50	-5.53%	SMA200	-11.70%	Volume	288,875	Change	1.55%

Aug-04-21 08:39AM	Alterity Therapeutics Announces New US Patent to Expand its Portfolio of Compounds for Neurodegenerative Diseases including Alzheimer's and Parkinson's PR Newswire +14.29%
Jul-30-21 09:05AM	Appendix 4C - Q4 FY21 Quarterly Cash Flow Report PR Newswire
Jul-15-21 09:52AM	Alterity Therapeutics Announces Publication of Data Demonstrating ATH434 is Neuroprotective and Improves Motor Function PR Newswire +7.91%
Jul-01-21 11:51AM	Want to Buy Alterity Therapeutics (ATHE) Stock? See This First. Benzinga +64.62%
07:50AM	Alterity Therapeutics granted a new US patent targeting major neurodegenerative diseases including Alzheimer's and Parkinson's PR Newswire
Jun-23-21 09:21AM	Alterity Therapeutics Limited Received European Union Regulatory Guidance for ATH434 Phase 2 Clinical Trial PR Newswire
Jun-07-21 11:04AM	Alterity Therapeutics (ASX:ATH) Is In A Good Position To Deliver On Growth Plans Simply Wall St. +10.29%
Apr-29-21 08:30AM	Alterity Therapeutics Limited Appendix 4C - Q3 FY21 Quarterly Cash Flow Report PR Newswire
Apr-21-21 09:25AM	Alterity's Stock Is Trading Higher As ATH434 Preserves Neurons, Motor Performance In Animal Model With Neurodegenerative Disorder Benzinga +15.20%
08:11AM	ATH434 protects brain cells and improves motor function in Parkinsonian disorder PR Newswire
Feb-26-21 07:45AM	Alterity to present at the 7th International Congress of Multiple System Atrophy PR Newswire -5.33%
Feb-09-21 08:53AM	Alterity Therapeutics announces funding from Michael J. Fox Foundation for ATH434 dose optimization for Parkinson's disease clinical trials PR Newswire +10.10%
Jan-07-21 08:00AM	Dr David Stamler Appointed CEO PR Newswire
Dec-21-20 08:30AM	Alterity and UniQuest partner to reverse bacterial resistance to antibiotics PR Newswire
Dec-09-20 09:46AM	Is Alterity Therapeutics (ASX:ATH) In A Good Position To Deliver On Growth Plans? Simply Wall St.
Nov-16-20 10:42AM	Alterity Therapeutics stock more than doubles on massive volume after new patent announcement MarketWatch +146.09%
08:42AM	Alterity announces approval of US patent for next generation compounds to treat neurodegenerative diseases PR Newswire
Oct-26-20 10:03PM	Alterity commences enrolling Multiple System Atrophy patients in bioMUSE Study PR Newswire
Aug-05-20 03:10PM	Why Alterity's Stock Is Trading Lower Today Benzinga -15.16%
Aug-04-20 09:07AM	Alterity's stock nearly triples on heavy volume after update on study of treatment for MSA, Parkinson's MarketWatch +154.07%
02:33AM	Alterity Therapeutics Shares Surge As Company Says Animal Testing Data Positive For MSA Drug Benzinga
Aug-03-20 09:33PM	New data independently confirms and extends laboratory findings and expands safety profile of ATH434 PR Newswire -7.53%
Jul-30-20 06:49PM	Alterity Releases Appendix 4C - Q4 FY20 Quarterly Cash Flow Report PR Newswire
Jul-01-20 08:12AM	The Daily Biotech Pulse: T2 Biosystems Launches COVID-19 Test, Akero Aces Midstage NASH Study, Aravive Added to Russell Indexes Benzinga +57.14%
Jun-29-20 11:14PM	Alterity Therapeutics meeting with US FDA provides development pathway for ATH434 PR Newswire
May-20-20 08:58PM	Alterity Therapeutics presents data on ATH434 to the American Academy of Neurology PR Newswire
Apr-30-20 04:35AM	Alterity Therapeutics Limited Releases Its Appendix 4C - Q3 FY20 Quarterly Cash Flow Report PR Newswire
Apr-21-20 05:50PM	How Should Investors React To Alterity Therapeutics Limited's (ASX:ATH) CEO Pay? Simply Wall St.
Feb-21-20 07:15PM	Imagine Owning Alterity Therapeutics (ASX:ATH) And Trying To Stomach The 86% Share Price Drop Simply Wall St. -5.21%
Nov-11-19 10:30PM	Companies Like Alterity Therapeutics (ASX:ATH) Can Be Considered Quite Risky Simply Wall St.
Sep-12-19 11:07PM	Does Alterity Therapeutics Limited's (ASX:ATH) CEO Salary Reflect Performance? Simply Wall St.
Jul-29-19 08:00AM	Alterity Therapeutics Announces Successful Completion of Phase 1 Clinical Trial Business Wire
Jul-11-19 09:31PM	Imagine Owning Alterity Therapeutics (ASX:ATH) And Trying To Stomach The 89% Share Price Drop Simply Wall St. -6.30%
May-06-19 08:00AM	Initial Data for Alterity Therapeutics Phase 1 Clinical Trial Released at American Academy of Neurology Annual Meeting Business Wire -5.38%
May-03-19 08:00AM	Alterity Therapeutics Presents at the American Academy of Neurology Annual Meeting Business Wire +14.81%

Alterity Therapeutics Limited researches and develops therapeutic drugs for the treatment of Parkinsonian's disease and other neurodegenerative diseases in Australia. The company's lead drug candidates is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing PBT2 for used as an antimicrobial agent. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. The company was founded in 1997 and is based in Melbourne, Australia.

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience